<DOC>
	<DOCNO>NCT00015847</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate interferon alfa may interfere growth cancer cell . Combining imatinib mesylate interferon alfa may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine imatinib mesylate interferon alfa treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate Interferon Alfa Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose interferon alfa administer imatinib mesylate patient chronic phase chronic myelogenous leukemia . ( Phase I close accrual 7/9/03 . ) - Determine safety tolerability regimen patient population . - Determine complete , major , minor cytogenetic response rate complete hematologic response rate patient 6 12 month treatment regimen . - Determine molecular response ( reverse transcriptase-polymerase chain reaction bcr-abl ) rate patient complete cytogenetic response 6 12 month treatment regimen . - Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation , multicenter study . - Phase I ( close accrual 7/9/03 ) : Patients receive oral imatinib mesylate daily begin day 1 interferon alfa ( IFN-A ) subcutaneously daily 3 time weekly begin day 14 . Courses repeat every 35 day 1 year absence disease progression unacceptable toxicity . After completion 1 year therapy , patient may receive additional therapy , provide patient benefit imatinib mesylate . IFN-A discontinued patient achieve molecular remission confirm 2 successive bone marrow sample . Imatinib mesylate discontinue patient achieve maintain molecular remission 2 year . Sequential dose escalation IFN-A follow sequential dose escalation imatinib mesylate . Cohorts 3-6 patient receive escalate dos IFN-A imatinib mesylate maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive imatinib mesylate IFN-A phase I establish MTD . Patients follow 30 day . PROJECTED ACCRUAL : Approximately 3-15 patient accrued phase I portion study . ( Phase I close accrual 7/9/03 . ) A total 40 patient accrue phase II portion study within 3-4 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically confirm chronic myelogenous leukemia ( CML ) Less 15 % blast peripheral blood bone marrow Less 30 % blast promyelocytes peripheral blood bone marrow Less 20 % basophil blood bone marrow Platelet count least 100,000/mm^3 No leukemia beyond bone marrow , blood , liver , spleen No chloroma Phase I ( close accrual 7/9/03 ) : Philadelphia ( Ph ) chromosomepositive CML chronic phase Phase II : Newly diagnose Ph chromosomepositive CML chronic phase Initial diagnosis within 6 month study No prior therapy CML except hydroxyurea and/or anagrelide hydrochloride Phase I ( close accrual 7/9/03 ) II : No identified sibling donor allogeneic stem cell transplantation elect firstline therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 method effective barrier contraception least 3 month study participation No serious uncontrolled medical condition No autoimmune disease No prior noncompliance medical regimen potential unreliability No prior grade 3 great nonhematologic toxicity due prior interferon ( phase I [ close accrual 7/9/03 ] ) PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior bone marrow peripheral blood stem cell transplantation At least 2 week since prior interferon alfa ( phase I [ close accrual 7/9/03 ] ) Chemotherapy : See Disease Characteristics At least 6 week since prior busulfan ( phase I [ close accrual 7/9/03 ] ) At least 2 week since prior cytarabine ( phase I [ close accrual 7/9/03 ] ) No concurrent chemotherapy Concurrent hydroxyurea allow first 3 month study Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 4 week since prior investigational agent imatinib mesylate ( phase I [ close accrual 7/9/03 ] ) No concurrent grapefruit juice Concurrent anagrelide hydrochloride allow first 3 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>